aripiprazole has been researched along with Depression, Involutional in 173 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 39 (22.54) | 29.6817 |
| 2010's | 108 (62.43) | 24.3611 |
| 2020's | 26 (15.03) | 2.80 |
| Authors | Studies |
|---|---|
| Bartova, L; Dold, M; Fabbri, C; Fugger, G; Kasper, S; Kautzky, A; Mendlewicz, J; Montgomery, S; Rujescu, D; Serretti, A; Souery, D; Swoboda, MMM; Zohar, J | 1 |
| Cipriani, A; Furukawa, TA; Furukawa, Y; Hamza, T; Ostinelli, EG; Salanti, G | 1 |
| Bhat, V; Demchenko, I; Espinola, CW; Frey, BN; Ho, K; Kennedy, SH; Khoo, Y; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Parmar, R; Ravindran, AV; Rotzinger, S | 1 |
| Bhat, V; Diep, C; Frey, BN; Gandhi, W; Kennedy, SH; Khoo, Y; Ladha, KS; Lam, RW; Lou, W; Milev, RV; Ravindran, AV; Rosenek, N; Rotzinger, S; Salomons, T; van Reekum, CM | 1 |
| Farzan, F; Foster, JA; Frey, BN; Husain, MI; Kennedy, SH; Kim, HK; Kloiber, S; Lam, RW; Milev, R; Müller, DJ; Mulsant, BH; Parikh, SV; Soares, CN; Tripathy, SJ; Turecki, G; Zai, G | 1 |
| Carter, B; Cleare, AJ; Emre, C; Gnanapragasam, S; Hampsey, E; Korotkova, L; Martín-Dombrowski, J; Marwood, L; Scott, F; Strawbridge, R; Taylor, RW; Young, AH | 1 |
| Chen, B; Ma, X; Wang, M; Yan, Y; Yang, X; Yin, L | 1 |
| Oravecz, R; Stuhec, M | 1 |
| Jha, MK; Mathew, SJ | 1 |
| Cain, K; Chung, I; Hardy, RE; Hirst, J; Loh, SHY; MacFarlane, M; Martins, LM; Morone, N; Panman, L; Pryde, KR; Serreli, R; Soleilhavoup, C; Travaglio, M; Yu, Y | 1 |
| Li, M; Li, W; Qiu, Z; Wang, J; Wu, H | 1 |
| Lu, Z; Wang, Y; Xun, G | 1 |
| Blumberger, DM; Buchalter, ELF; Dixon, D; Karp, JF; Lenze, EJ; Miller, JP; Mulsant, BH; Oughli, HA; Reynolds, CF | 1 |
| Alders, GL; Arnott, SR; Davis, A; Frey, BN; Hall, GB; Harris, J; Hassel, S; Kennedy, SH; Lam, RW; MacQueen, GM; Milev, R; Minuzzi, L; Raamana, PR; Sassi, RB; Strother, SC; Suh, JS; Zamyadi, M | 1 |
| Antoun Reyad, A; Girgis, E; Mishriky, R | 1 |
| Blier, P; Foster, JA; Frey, BN; Kennedy, SH; Lam, RW; MacQueen, G; Milev, R; Müller, DJ; Parikh, SV; Quilty, LC; Ravindran, AV; Rotzinger, S; Soares, CN; Turecki, G; Uher, R | 1 |
| Aslam, M; Chen, P; Davis, L; Hicks, PB; Iranmanesh, A; Johnson, GR; Jurjus, G; Lauro, K; Michalets, J; Mohamed, S; Pilkinton, P; Rao, SD; Sapra, M; Sevilimedu, V; Thase, M; Wilcox, JA; Zisook, S | 1 |
| Mishra, VC; Swami, MK | 1 |
| Kennedy, SH; Lam, RW; Uher, R | 1 |
| Alciati, A; Caldirola, D; Cuniberti, F; Daccò, S; De Berardis, D; Perna, G | 1 |
| Bodoukhin, N; Botros, M; Luca, L; Taylor, R | 1 |
| Bhat, V; Chakrabarty, T; Frey, BN; Giacobbe, P; Kennedy, SH; Lam, RW; Lou, W; Michalak, EE; Milev, RV; Morton, E; Müller, DJ; Parikh, SV; Rotzinger, S | 1 |
| Chakrabarty, T; Frey, BN; Kennedy, SH; Lam, RW; McInerney, SJ; Milev, RV; Müller, DJ; Rotzinger, S; Torres, IJ | 1 |
| Bhat, V; Chakrabarty, T; Frey, BN; Giacobbe, P; Kennedy, SH; Lam, RW; Lou, W; McInerney, S; Michalak, EE; Milev, RV; Morton, E; Müller, DJ; Parikh, SV; Rotzinger, S | 1 |
| Futamura, T; Hirose, T; Kikuchi, T; Maeda, K; McQuade, RD; Suzuki, M | 1 |
| Allen, TA; Frey, BN; Harkness, KL; Kennedy, SH; Lam, RW; Milev, R; Mueller, DJ; Quilty, LC; Uher, R | 1 |
| Habermann, TJ; Seshadri, A; Singh, B; Wermers, ME | 1 |
| Albers, LJ; Anderson, KD; Anderson, WG; Aslam, M; Beresford, T; Carrera, CJ; Chen, P; Connolly, KR; D'Souza, DC; Davis, LL; Fareed, A; Fernando, R; Finkel, MS; Fischer, BA; Gleason, TC; Hicks, PB; Huang, GD; Hurley, R; Iranmanesh, A; Johnson, GR; Jones, KA; Juergens, TM; Jurjus, G; Kasckow, J; Khatkhate, G; Klatt, M; LaMotte, J; Larson, G; Lawrence, DD; Lieske, S; Little, JT; Loreck, DJ; Marri, S; Mayeda, AR; Michalets, JP; Mohamed, S; Nasdahl, CS; Niculescu, AB; Nogues, CA; Pilkinton, PD; Planeta, B; Ramaswamy, S; Rao, SD; Rosenlicht, N; Sapra, M; Scrymgeour, A; Suppes, T; Tal, I; Tapp, A; Thase, ME; Thompson, SI; Vertrees, JE; Villarreal, G; Weingart, K; Westermeyer, J; Wilcox, JA; Williams, SS; Winston, JL; Yoon, G; Yoon, J; Zisook, S | 1 |
| Blumberger, DM; DiNapoli, EA; Gebara, MA; Karp, JF; Kasckow, J; Lenze, EJ; Mulsant, BH; Reynolds, CF | 1 |
| Lui, KJ | 1 |
| Bramness, JG; Handal, M; Hartz, I; Hjellvik, V; Nesvåg, R; Skurtveit, S | 1 |
| Aladeen, T; Capote, H; Lee, Y; McIntyre, RS; Rainka, M; Rong, C; Westphal, E | 1 |
| Hibino, H; Inoue, Y; Mikami, K; Suzuki, H | 1 |
| Kamijima, K; Kimura, M; Kitayama, Y; Kuwahara, K; Tadori, Y | 1 |
| Carvalho, AF; Hidalgo-Mazzei, D; Murru, A; Pacchiarotti, I; Samalin, L; Verdolini, N; Vieta, E; Young, AH | 1 |
| Burudpakdee, C; Greene, M; Hartry, A; Seetasith, A | 1 |
| Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P | 1 |
| Fukuta, Y; Kamijima, K; Yamamura, K; Yasuda, M | 1 |
| Allen, TA; Frey, BN; Kennedy, SH; Lam, RW; MacQueen, GM; Milev, R; Müller, DJ; Quilty, LC; Rizvi, SJ; Uher, R | 1 |
| Dias Alves, M; Micoulaud-Franchi, JA; Simon, N; Vion-Dury, J | 1 |
| Johnson, GR; Mohamed, S; Park, A; Scrymgeour, A; Yoon, J; Zisook, S | 1 |
| Blier, P; Downar, J; Evans, KR; Farzan, F; Foster, JA; Frey, BN; Giacobbe, P; Hall, GB; Harkness, KL; Hassel, S; Ismail, Z; Kennedy, SH; Lam, RW; Leri, F; MacQueen, GM; McInerney, S; Milev, RV; Minuzzi, L; Müller, DJ; Parikh, SV; Placenza, FM; Quilty, LC; Ravindran, AV; Rotzinger, S; Sassi, RB; Soares, CN; Strother, SC; Turecki, G; Uher, R; Vaccarino, AL; Vila-Rodriguez, F; Yu, J | 1 |
| Kahn, DA | 1 |
| Liu, QS; Luo, T; Wei, B; Yang, YJ | 1 |
| Beach, SR; Celano, CM; Chen, JA; Ptaszek, LM | 1 |
| Chen, P; Davis, L; Hicks, P; Johnson, GR; Mohamed, S; Tal, I; Thase, M; Vertrees, J; Zhao, Y; Zisook, S | 1 |
| Lenze, EJ; Locke, AE; Miller, JP; Müller, DJ; Mulsant, BH; Newcomer, JW; Nicol, GE; Oughli, H; Peterson, TR; Reynolds, CF; Yingling, MD; Zhong, Y | 1 |
| Horikoshi, S; Ichinose, M; Ito, M; Kaneko, H; Kanno-Nozaki, K; Miura, I; Watanabe, K; Yabe, H; Yamamoto, S | 1 |
| Citrome, LL; Manning, JS; McIntosh, D; McIntyre, RS | 1 |
| Hirakawa, M; Kunisawa, K; Libo, Z; Lu, Q; Mori, Y; Mouri, A; Nabeshima, T; Saito, K; Teshigawara, T; Yamamoto, Y; Yang, Y | 1 |
| Begley, AE; Blumberger, D; Butters, M; Dew, MA; Joel, I; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF | 1 |
| Cassiello, C; Dording, C; Fava, M; King, F; Mischoulon, D; Pencina, M | 1 |
| Cho, SJ; Choi, JH; Hahn, SW; Han, C; Jeon, HJ; Jon, DI; Jun, TY; Kim, SG; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Park, EJ; Seo, HJ | 1 |
| Higuchi, T; Ishigooka, J; Kamijima, K; Kanba, S; Kinoshita, T; Koyama, T; Ohmori, T; Ozaki, N | 1 |
| Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Wang, SM | 1 |
| Han, C; Jeon, HJ; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Seo, HJ; Wang, SM | 1 |
| Chibnall, JT; Conway, CR; Cornell, ME; Cumming, P; Gangwani, S; Gebara, MA; McConathy, JE; Mintun, MA; Perantie, DC; Price, JL; Sheline, YI | 1 |
| Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS | 1 |
| Baker, RA; Berman, RM; Eudicone, JM; Laubmeier, KK; Marcus, RN; McQuade, RD; Nelson, JC; Rahman, Z; Sheehan, JJ | 1 |
| Berman, RM; Hatch, A; Largay, K; Marler, SV; Nelson, JC; Sheehan, JJ; Stewart, TD | 1 |
| Hu, JY; Huang, A; Liu, YY; Liu, ZL; Wang, LM; Wen, XJ | 1 |
| Philip, NS | 1 |
| Higuchi, T; Kamijima, K; Kato, M; Ono, H; Otsubo, T; Ozaki, N | 1 |
| Makkos, Z | 1 |
| Baker, RA; Berman, RM; Cain, ZJ; Clayton, AH; Forbes, RA; Marcus, R; Marler, SV; Sheehan, JJ; Thase, ME | 1 |
| Chang, CC; Chang, HA; Chen, TY; Chu, CS; Tzeng, NS | 1 |
| Berman, RM; Casey, DE; Eudicone, JM; Laubmeier, KK; Marcus, R; Rahman, Z; Sheehan, J | 1 |
| Sharma, V; Sommerdyk, C; Xie, B | 1 |
| Baker, RA; Dunlop, BW; Eudicone, JM; McCabe, B; Sheehan, JJ | 1 |
| Chiou, CC; Lane, HY; Lin, CY; Tsai, GE; Wang, HS; Wu, VY; Wu, YH | 1 |
| Hou, YC; Lai, CH | 1 |
| Huh, L; Lee, BJ | 1 |
| Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R | 1 |
| Biswas, K; Chen, P; Davis, LL; Gerrity, M; Gleason, TC; Guarino, PD; Hicks, P; Huang, GD; Johnson, GR; Kelada, A; Kilbourne, AM; Kirkwood, KA; Lawrence, DD; LeGwin, M; Marder, S; Mohamed, S; Vertrees, JE; Weingart, K; Yoon, J; Young, IT; Zisook, S | 1 |
| Alpert, JE; Doros, GD; Fava, M; Fisher, LB; Freeman, MP; Henry, M; Huz, I | 1 |
| Flynn, A; Macaluso, M; Preskorn, S | 3 |
| Citrome, L | 2 |
| Stahl, SM | 1 |
| Taylor, WD | 1 |
| Aizenstein, HJ; Anderson, SJ; Blumberger, D; Butters, MA; Dew, MA; Diniz, BS; Kaneriya, SH; Karp, JF; Lenze, EJ; Lotrich, F; Mulsant, BH; Reynolds, CF; Robbins-Welty, GA; Smagula, SF | 1 |
| Macaluso, M; Preskorn, SH | 1 |
| Anderson, SJ; Blumberger, DM; Butters, MA; Dew, MA; Diniz, BS; Karp, JF; Lenze, EJ; Lotrich, FE; Mulsant, BH; Reynolds, CF; Smagula, SF; Wallace, ML | 1 |
| Chen, P; Davis, LL; Hicks, P; Huang, GD; Iranmanesh, A; Johnson, GR; Mohamed, S; Pilkinton, PD; Rao, S; Sapra, M; Tal, I; Vertrees, JE; Weingart, K; Wilcox, JA; Yoon, J; Zisook, S | 1 |
| Blumberger, DM; Hsu, JH; Karp, JF; Lavretsky, H; Lenze, EJ; Mulsant, BH; Reynolds, CF; Roose, SP | 1 |
| Alpert, JE; Baer, L; Clain, AJ; Cusin, C; Fava, M; Hylek, L; Ionescu, DF; Mischoulon, D; Soskin, DP; Yeung, AS | 1 |
| Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E | 1 |
| Fujishiro, H; Iwamoto, K; Ozaki, N | 1 |
| Cheon, EJ; Koo, BH; Lee, JH; Lee, KH; Lee, SJ; Park, YW; Sung, HM | 1 |
| Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM | 1 |
| Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
| Lyseng-Williamson, KA; Scott, LJ; Weber, J | 1 |
| Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K | 1 |
| Khan, A | 1 |
| Ammerman, DK; Coley, KC; Fabian, TJ; Ganguli, R; Kim, E; Kim, MS; Saul, MI; Scipio, TM; Whitehead, R | 1 |
| Mathew, SJ | 1 |
| Denninger, JW; Dording, C; Fava, M; Hilliker, S; Homberger, C; Matthews, JD; Park, L; Rooney, K; Siefert, C; Sklarsky, K; van Nieuwenhuizen, AO | 1 |
| Carroll, BJ | 1 |
| Tsai, AC | 1 |
| Kyomen, HH; Whitfield, TH | 1 |
| Berman, RM; Carlson, BX; Fava, M; Marcus, RN; Nelson, CJ; Pikalov, A; Qi, Y; Thase, ME; Tran, QV; Trivedi, MH; Yang, H | 1 |
| Butters, MA; Dew, MA; Driscoll, HC; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M | 1 |
| Corey-Lisle, PK; Guo, Z; Kim, E; Lennox, RD; Pikalov, A; Trivedi, MH | 1 |
| Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM | 1 |
| Adson, D; Berman, RM; Carson, WH; Fava, M; Hazel, J; Marcus, RN; McQuade, RD; Swanink, R; Taylor, L; Thase, ME; Trivedi, MH | 1 |
| Preskorn, SH | 1 |
| Baker, RA; Berman, RM; Fava, M; Marcus, RN; Pikalov, A; Thase, ME; Tran, QV; Wisniewski, SR; Yang, H | 1 |
| Baker, RA; Berman, RM; Carlson, BX; Eudicone, JM; Mankoski, R; Nelson, JC; Pikalov, A; Tran, QV | 1 |
| Pae, CU | 1 |
| Carlson, BX; Chen, CC; Guo, Z; Kan, HJ; Kim, E; Pikalov, A; Tran, QV; Wisniewski, SR | 1 |
| Ansseau, M; Pitchot, W | 1 |
| Radics, J | 1 |
| Lai, CH | 3 |
| Kitamura, H; Someya, T; Yokoyama, Y | 1 |
| Berman, RM; Carlson, BX; Eudicone, JM; Marchant, BK; Marcus, RN; Martin, ML; Pikalov, A; Reimherr, FW; Tran, QV | 1 |
| Tényi, T; Vörös, V | 1 |
| Berman, RM; Carlson, BX; Eudicone, JM; Khan, A; Pikalov, A; Tran, QV; Trivedi, MH; Weisler, RH; Yang, H | 1 |
| Andersson, C; Berman, RM; Carlson, BX; Eudicone, JM; Forbes, RA; Nelson, JC; Steffens, DC; Tran, QV; Yang, H | 1 |
| Chen, J; Gao, K; Kemp, DE | 1 |
| Guerdjikova, A; Keck, PE; McElroy, SL; Mori, N | 1 |
| Chang, CH; Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW | 1 |
| Ramaswamy, S; Selvaraj, V; Sharma, A; Wilson, D | 1 |
| Depping, AM; Gaudchau, A; Kissling, W; Komossa, K; Leucht, S | 1 |
| Leinonen, E; Valtonen, HM; Viikki, M | 1 |
| Katzman, MA | 1 |
| Blier, P; Blondeau, C | 1 |
| Forbes, A; Pae, CU; Patkar, AA | 1 |
| Leelahanaj, T | 1 |
| Frost, M; Marcus, RM; McQuade, RD; Sanchez, R | 1 |
| Fikretoglu, D; Liu, A; McIntosh, D; Richardson, JD | 1 |
| Catapano, F; Esposito, G; Fabrazzo, M; Maj, M; Monteleone, P; Perris, F | 1 |
| Bagalman, E; Carls, GS; Curkendall, SM; Forbes, RA; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME | 1 |
| Jang, FL; Lin, CH; Lin, SH | 1 |
| Fava, M; Hsieh, WH; Levy, M; Mischoulon, D; Papakostas, GI; Pencina, MJ; Pet, LR; Pollack, MH; Ward, S; Witte, J | 1 |
| Dalton, ED; Dording, CM; Fava, M; Mischoulon, D; Pencina, MJ | 1 |
| Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW | 1 |
| Baker, RA; Berman, RM; Camacho, TA; Chambers, JS; Eudicone, JM; Forbes, RA; Muzina, DJ | 1 |
| Tomba, E | 1 |
| Bou Khalil, R; Dahdah, P; Kahn, DA; Richa, S | 1 |
| Fava, M; Flynn, M; Harper, L; Iosifescu, D; Levy, M; Mischoulon, D; Pencina, M; Pollack, M; Rickels, K; Witte, J | 1 |
| Baker, RA; Bellocchio, EE; Berman, RM; Eudicone, JM; Marcus, RN; McQuade, RD; Nelson, JC; Rollin, LM; Thase, ME | 1 |
| Baker, RA; Forbes, RA; Jing, Y; Oster, G; Papakostas, GI; Taneja, C | 1 |
| Lin, CC; Lin, HY; Liu, CC | 1 |
| Cho, AR; Kang, WS; Park, JK | 1 |
| Forbes, RA; Guo, Z; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME | 1 |
| Choi, JE; Han, DH; Kim, SM; Min, KJ; Renshaw, PF | 1 |
| Doros, G; Fava, M; Meisner, A; Pencina, M; Rybin, D | 1 |
| Hellerstein, DJ | 1 |
| Malik, AR; Ravasia, S | 1 |
| Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA | 1 |
| Baldessarini, RJ; Grant, MJ | 1 |
| Nemeroff, CB; Simon, JS | 1 |
| Alpert, JE; Burns, AM; Fava, M; Kinrys, G; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Worthington, JJ | 1 |
| Sharma, A; Sorrell, JH | 1 |
| Maytal, G; Ostacher, M; Stern, TA | 1 |
| Jun, TY; Lee, C; Masand, PS; Pae, CU; Paik, IH; Patkar, AA | 1 |
| Fiedler, U; Wolf, J | 1 |
| Carroll, BT; Goforth, HW | 1 |
| Baghai, TC; Born, C; Eser, D; Häfner, S; Hecht, S; Hermisson, I; Nothdurfter, C; Rupprecht, R; Schüle, C | 1 |
| Berman, RM; Carson, WH; Corey-Lisle, PK; Khan, A; Marcus, RN; McQuade, RD; Swanink, R | 1 |
| Burrows, G; Jefferys, D | 1 |
| Arnold, KK; Yager, J | 1 |
| Chou, YH; Su, TP; Yang, KC | 1 |
| Papakostas, GI; Shelton, RC | 1 |
| Bowden, CL; Carson, WH; Jonas, A; Khan, A; Marcus, RN; McQuade, RD; Owen, R; Thase, ME; Wu, X | 1 |
| Chriki, LS; Dunn, RT; Filkowski, MM; Ghaemi, SN; Stan, VA | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
31 review(s) available for aripiprazole and Depression, Involutional
| Article | Year |
|---|---|
Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Reproducibility of Results | 2022 |
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression.
Topics: Adult; Aripiprazole; Depression; Depressive Disorder, Major; Humans; Ketamine; Risperidone | 2023 |
Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Network Meta-Analysis; Olanzapine; Quetiapine Fumarate; Risperidone | 2022 |
Bupropion XL unapproved use in the prisons: Two cases focused on the bupropion pharmacology.
Topics: Adult; Aripiprazole; Bupropion; Depressive Disorder, Major; Dopamine; Humans; Mirtazapine; Norepinephrine; Prisons; Quetiapine Fumarate; Randomized Controlled Trials as Topic | 2022 |
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; United States | 2023 |
Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Network Meta-Analysis; Olanzapine; Quetiapine Fumarate | 2023 |
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2020 |
Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review.
Topics: Adult; Antidepressive Agents; Aripiprazole; Child; Child Abuse; Clinical Decision-Making; Clinical Trials as Topic; Depressive Disorder, Major; Escitalopram; Humans; Observational Studies as Topic; Precision Medicine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2021 |
Discovery research and development history of the dopamine D
Topics: Aripiprazole; Depressive Disorder, Major; Dopamine; Dopamine Agonists; Humans; Quinolones; Research; Thiophenes; United States | 2021 |
Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Tardive Dyskinesia | 2021 |
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Lithium; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Practice Guidelines as Topic; Quetiapine Fumarate; Thiazoles; Valproic Acid | 2018 |
Aripiprazole with digital ingestion tracking (Abilify MyCite).
Topics: Antipsychotic Agents; Aripiprazole; Biosensing Techniques; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder, Major; Gastrointestinal Absorption; Humans; Schizophrenia; Signal Processing, Computer-Assisted | 2019 |
Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Synergism; Humans; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Risperidone; Treatment Outcome; Young Adult | 2014 |
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Male; Medication Errors | 2015 |
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dystonia; Humans; Tardive Dyskinesia | 2016 |
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome | 2008 |
Aripiprazole: in major depressive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Disability Evaluation; Drug Tolerance; Humans; Piperazines; Quinolones | 2008 |
Current evidence for aripiprazole as augmentation therapy in major depressive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Chemotherapy, Adjuvant; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Piperazines; Quinolones; Treatment Outcome | 2008 |
Treatment-resistant depression: recent developments and future directions.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Combined Modality Therapy; Deep Brain Stimulation; Depressive Disorder, Major; Drug Resistance; Electroconvulsive Therapy; Humans; Piperazines; Prognosis; Quinolones; Tetrahydrofolates; Transcranial Magnetic Stimulation; Treatment Outcome; Vagus Nerve Stimulation | 2008 |
Treatment options for the patient who does not respond well to initial antidepressant therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Drug Approval; Drug Resistance; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Piperazines; Psychotropic Drugs; Quinolones; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Vagus Nerve Stimulation | 2009 |
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult | 2009 |
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biostatistics; Clinical Trials as Topic; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Epidemiologic Measurements; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones | 2010 |
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
Topics: Adult; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Sulpiride | 2011 |
Therapeutic potential of new second generation antipsychotics for major depressive disorder.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic | 2010 |
Second-generation antipsychotics for major depressive disorder and dysthymia.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dysthymic Disorder; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride | 2010 |
Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Anxiety Disorders; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Mental Disorders; Piperazines; Quinolones | 2011 |
Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2011 |
Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.
Topics: Animals; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Drug Interactions; Humans; Piperazines; Quinolones | 2011 |
Lycanthropy as a culture-bound syndrome: a case report and review of the literature.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior Control; Citalopram; Cultural Characteristics; Culture; Delusions; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethnopsychology; Female; Humans; Lebanon; Middle Aged; Mythology; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2012 |
Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Topics: Adult; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome | 2012 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles | 2008 |
56 trial(s) available for aripiprazole and Depression, Involutional
| Article | Year |
|---|---|
Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Escitalopram; Humans; Pain; Pain Measurement; Treatment Outcome | 2022 |
Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Cognition; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2024 |
Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
Topics: Algorithms; Antidepressive Agents; Anxiety Disorders; Aripiprazole; Clinical Decision Rules; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Likelihood Functions; Prospective Studies; Recurrence; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
Topics: Adult; Antidepressive Agents; Aripiprazole; Cerebral Cortex; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neuroimaging; Outcome Assessment, Health Care | 2020 |
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Aripiprazole; Citalopram; Depressive Disorder, Major; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Lethargy; Male; Middle Aged; Young Adult | 2020 |
Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Single-Blind Method; Stress Disorders, Post-Traumatic; Young Adult | 2020 |
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Biomarkers; Canada; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Drug Therapy, Combination; Escitalopram; Female; Humans; Male; Middle Aged; Young Adult | 2021 |
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Drug Resistance; Drug Substitution; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Remission Induction; United States; Veterans | 2017 |
Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
Topics: Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2018 |
Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nasopharyngitis; Outcome Assessment, Health Care; Sertraline; Single-Blind Method; Young Adult | 2018 |
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Aripiprazole; Bupropion; Cost-Benefit Analysis; Depression; Depressive Disorder, Major; Drug Substitution; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; United States; United States Department of Veterans Affairs; Veterans | 2018 |
Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outpatients; Treatment Outcome; Young Adult | 2019 |
General Predictors and Moderators of Depression Remission: A VAST-D Report.
Topics: Adult; Adverse Childhood Experiences; Aged; Aged, 80 and over; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Drug Substitution; Drug Therapy, Combination; Employment; Female; Grief; Humans; Life Tables; Male; Middle Aged; Prognosis; Quality of Life; Remission Induction; Severity of Illness Index; Single-Blind Method; United States; United States Department of Veterans Affairs; Young Adult | 2019 |
Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole.
Topics: Absorptiometry, Photon; Adiposity; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Genome-Wide Association Study; Humans; Male; Polymorphism, Single Nucleotide; Venlafaxine Hydrochloride; Weight Gain | 2019 |
Low- and high-dose aripiprazole augmentation and plasma levels of homovanillic acid in major depressive disorder: A randomized, open-label study.
Topics: Adult; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2019 |
Dynamic prediction of treatment response in late-life depression.
Topics: Age of Onset; Aged; Aged, 80 and over; Aripiprazole; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Remission Induction; Severity of Illness Index; Signal Detection, Psychological; Symptom Assessment; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Hostility; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Young Adult | 2013 |
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
Topics: Adult; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Secondary Prevention; Treatment Outcome | 2013 |
Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Asian People; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Time Factors; Treatment Outcome | 2013 |
Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2014 |
Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones | 2014 |
Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.
Topics: Adult; Animals; Antidepressive Agents; Aripiprazole; Caudate Nucleus; Citalopram; Corpus Striatum; Depressive Disorder, Major; Dihydroxyphenylalanine; Dopamine; Dopamine Agonists; Drug Synergism; Female; Humans; Magnetic Resonance Imaging; Male; Piperazines; Positron-Emission Tomography; Quinolones; Sample Size; Single-Blind Method; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2014 |
Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Odds Ratio; Piperazines; Psychomotor Agitation; Quinolones; Severity of Illness Index | 2014 |
Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2015 |
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Topics: Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Norepinephrine; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior; Treatment Outcome | 2014 |
Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales | 2014 |
Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Benzhydryl Compounds; Cytochrome P-450 CYP3A Inducers; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Middle Aged; Modafinil; Piperazines; Quinolones; Wakefulness-Promoting Agents; Young Adult | 2015 |
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Remission Induction; Research Design; Time Factors | 2015 |
The Role of Anger/Hostility in Treatment-Resistant Depression: A Secondary Analysis From the ADAPT-A Study.
Topics: Adult; Anger; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Hostility; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Surveys and Questionnaires | 2015 |
Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Aripiprazole; Comorbidity; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Executive Function; Female; Follow-Up Studies; Humans; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Set, Psychology; Severity of Illness Index; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Aripiprazole; Bupropion; Comorbidity; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; United States; Veterans; Young Adult | 2016 |
Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Late Onset Disorders; Male; Middle Aged; Prognosis; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
Topics: Adult; Antidepressive Agents; Aripiprazole; Central Nervous System Stimulants; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Sertraline; Treatment Outcome | 2017 |
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Topics: Antidepressive Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Impulsive Behavior; Male; Middle Aged; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Sleep; Thiophenes; Treatment Outcome | 2017 |
Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamine Uptake Inhibitors; Drug Synergism; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Selective Serotonin Reuptake Inhibitors | 2017 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Quinolones; Sertraline; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2010 |
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Body Weight; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Quinolones; Treatment Outcome | 2008 |
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Feasibility Studies; Female; Humans; Male; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Thiophenes; Venlafaxine Hydrochloride | 2009 |
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome | 2009 |
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Failure; Young Adult | 2009 |
Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2010 |
A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole.
Topics: Adolescent; Adult; Aged; Aripiprazole; Cross-Sectional Studies; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Physician's Role; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Young Adult | 2010 |
Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Suicidal Ideation; Time Factors; Young Adult | 2011 |
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Young Adult | 2011 |
The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Asian People; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Drug Therapy, Combination; Humans; Models, Economic; Outpatients; Piperazines; Quality-Adjusted Life Years; Quinolones; Thailand; Treatment Outcome | 2010 |
Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clomipramine; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline; Treatment Outcome; Young Adult | 2011 |
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2012 |
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Constipation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Placebos; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; United States; Weight Gain; Young Adult | 2012 |
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Functional Neuroimaging; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurons; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors | 2013 |
Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2005 |
Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Neurologic Examination; Personality Inventory; Piperazines; Quinolones | 2007 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Severity of Illness Index; Treatment Outcome | 2007 |
Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones | 2008 |
A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Lorazepam; Male; Middle Aged; Nausea; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
86 other study(ies) available for aripiprazole and Depression, Involutional
| Article | Year |
|---|---|
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cross-Sectional Studies; Depressive Disorder, Major; Drug Therapy, Combination; Europe; Female; Humans; Male; Middle Aged; Quetiapine Fumarate; Retrospective Studies; Treatment Outcome | 2022 |
Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.
Topics: Aripiprazole; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Escitalopram; Humans; Treatment Outcome | 2022 |
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study.
Topics: Aripiprazole; Biomarkers; Canada; Depressive Disorder, Major; Double-Blind Method; Endocannabinoids; Escitalopram; Genome-Wide Association Study; Humans; RNA, Messenger; Treatment Outcome | 2022 |
The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drosophila melanogaster; Electron Transport; Mice | 2023 |
Interest-Activity Dimension and Response to Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Humans; Quinolones | 2020 |
Dr Uher and Colleagues Reply.
Topics: Aripiprazole; Citalopram; Depressive Disorder, Major; Humans | 2020 |
Joy Journal: A Behavioral Activation Technique Used in the Treatment of Late-Life Depression Associated With Hopelessness During the COVID-19 Pandemic.
Topics: Aged; Antidepressive Agents; Aripiprazole; Cognitive Behavioral Therapy; COVID-19; Depressive Disorder, Major; Female; Fluoxetine; Happiness; Hope; Hospitalization; Humans; SARS-CoV-2; Suicidal Ideation; Unemployment | 2021 |
Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report.
Topics: Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Quality of Life; Treatment Outcome | 2021 |
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Aripiprazole; Canada; Depressive Disorder, Major; Drug Monitoring; Drug Therapy, Combination; Escitalopram; Female; Humans; Male; Physical Functional Performance; Psychiatric Status Rating Scales; Quality of Life; Social Interaction; Treatment Outcome | 2021 |
Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report.
Topics: Aripiprazole; Depression; Depressive Disorder, Major; Escitalopram; Humans; Neuroticism | 2021 |
Estimation of the relative difference (or relative risk reduction) under the sequential parallel comparison design.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Models, Statistical; Monte Carlo Method; Randomized Controlled Trials as Topic; Research Design | 2019 |
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Disorder, Major; Female; Humans; Incidence; Infant; Male; Mental Disorders; Norway; Olanzapine; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia | 2018 |
The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; New York; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Effect of aripiprazole monotherapy in a patient presenting with delayed sleep phase syndrome associated with depressive symptoms.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Male; Sleep Disorders, Circadian Rhythm | 2018 |
Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Topics: Adult; Age Factors; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Expenditures; Health Resources; Health Services; Humans; Insurance Claim Review; Lurasidone Hydrochloride; Male; Middle Aged; Models, Econometric; Quetiapine Fumarate; Quinolones; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors; Thiophenes; Time-to-Treatment | 2018 |
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2018 |
Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prospective Studies; Selective Serotonin Reuptake Inhibitors | 2018 |
Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report.
Topics: Adolescent; Adult; Anhedonia; Antidepressive Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Punishment; Reward; Young Adult | 2019 |
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Clozapine; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Young Adult | 2018 |
Commentary: Aripiprazole: The Second Wave of the Second-generation Antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agents; History, 21st Century; Humans; Mental Disorders; Psychotic Disorders; Schizophrenia | 2019 |
Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: A case report.
Topics: Adolescent; Amenorrhea; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Galactorrhea; Humans; Hyperprolactinemia; Menstruation Disturbances; Prolactin; Receptors, Dopamine D2 | 2019 |
Case 9-2019: A 62-Year-Old Man with Atrial Fibrillation, Depression, and Worsening Anxiety.
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Antidepressive Agents; Anxiety Disorders; Aripiprazole; Arrhythmias, Cardiac; Atrial Fibrillation; Depressive Disorder, Major; Diagnosis, Differential; Electrocardiography; Humans; Male; Middle Aged; Pacemaker, Artificial; Sotalol | 2019 |
Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Arousal; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Drug Approval; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Practice Patterns, Physicians'; Quality of Life; Quetiapine Fumarate; Quinolones; Sleep Initiation and Maintenance Disorders; Thiophenes | 2019 |
Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression.
Topics: Animals; Aripiprazole; Behavior, Animal; Depression; Depressive Disorder, Major; Disease Models, Animal; Dopamine; Fluoxetine; Hippocampus; Male; Mice; Mice, Inbred C57BL; Nucleus Accumbens; Prefrontal Cortex; Serotonin; Signal Transduction; Stress, Psychological; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase | 2019 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2014 |
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Time Factors | 2014 |
An aripiprazole discontinuation syndrome.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2013 |
[Antipsychotics -- do they exist?].
Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Corpus Striatum; Depressive Disorder, Major; Dopamine; Dopamine Agents; Humans; Obsessive-Compulsive Disorder; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Stress, Psychological; Thinking | 2014 |
Killing two birds with one stone: the potential role of aripiprazole for patients with comorbid major depressive disorder and nicotine dependence via altering brain activity in the anterior cingulate cortex.
Topics: Antidepressive Agents, Second-Generation; Aripiprazole; Brain; Brain Diseases; Bupropion; Comorbidity; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Dopaminergic Neurons; Gyrus Cinguli; Humans; Nicotine; Serotonin; Smoking; Tobacco Use Disorder; Treatment Outcome | 2014 |
Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depression, Postpartum; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2015 |
How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine.
Topics: Adult; Antidepressive Agents; Anxiety; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Precision Medicine; Prognosis; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Self Report; Treatment Outcome | 2014 |
Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dibenzothiazepines; Drug Synergism; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hospitalization; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Taiwan; Treatment Outcome | 2014 |
Aripiprazole monotherapy can relieve ruminations in a case with nonpsychotic depression.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Male | 2014 |
Efficacy of aripiprazole in antidepressants-induced tardive dystonia and tardive dyskinesia: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2015 |
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes | 2015 |
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clozapine; Depressive Disorder, Major; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Male; United States; United States Food and Drug Administration | 2016 |
Mechanism of action of brexpiprazole: comparison with aripiprazole.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes | 2016 |
Moderators of Remission in Patients With Late-Life Depression: Where Do We Go Next?
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Executive Function; Female; Humans; Male; Set, Psychology | 2016 |
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Dystonia; Humans; Incidence; Risk Factors; Tardive Dyskinesia; United States | 2016 |
Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Statistics, Nonparametric; Trail Making Test; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Effect of aripiprazole augmentation for depressive symptoms changes with progression of Lewy body disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Disease Progression; Drug Synergism; Female; Humans; Lewy Body Disease | 2017 |
The safety of the electroconvulsive therapy-aripiprazole combination: four case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Inpatients; Middle Aged; Piperazines; Quinolones; Safety; Schizophrenia | 2008 |
Predictors of aripiprazole treatment continuation in hospitalized patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Patient Discharge; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome | 2008 |
An open study of aripiprazole and escitalopram for psychotic major depressive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Selective Serotonin Reuptake Inhibitors | 2009 |
Aripiprazole in refractory depression?
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2009 |
Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2009 |
Psychosis in the elderly.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Comorbidity; Cyclohexanols; Delirium; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Memantine; Nootropic Agents; Piperazines; Psychotherapy; Psychotic Disorders; Quinolones; Risk Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
Topics: Adult; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Data Interpretation, Statistical; Depressive Disorder, Major; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Socioeconomic Factors; Treatment Failure | 2009 |
Potential utility of aripiprazole monotherapy for the treatment of major depressive disorder comorbid with obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Treatment Outcome | 2009 |
Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
Aripiprazole, hypertension, and confusion.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Confusion; Depressive Disorder, Major; Female; Humans; Hypertension; Piperazines; Quinolones | 2010 |
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care].
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses | 2010 |
Aripiprazole-induced gray matter growth in a patient with major depressive disorder with panic disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Comorbidity; Depressive Disorder, Major; Female; Humans; Magnetic Resonance Imaging; Organ Size; Panic Disorder; Piperazines; Quinolones; Receptors, Serotonin | 2010 |
Aripiprazole monotherapy in a patient with major depressive disorder.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Piperazines; Quinolones; Treatment Outcome | 2010 |
[Use of aripiprazole in the treatment of catatonia].
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Depressive Disorder, Major; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Performance; Quinolones; Schizoid Personality Disorder; Schizophrenia, Catatonic | 2010 |
Aripiprazole-related subcortical growth in a patient with major depressive disorder and panic disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Depressive Disorder, Major; Humans; Male; Panic Disorder; Piperazines; Quinolones; Treatment Outcome | 2010 |
Aripiprazole augmentation induced hypertension in major depressive disorder: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Synergism; Duloxetine Hydrochloride; Female; Humans; Hypertension; Middle Aged; Piperazines; Quinolones; Thiophenes | 2011 |
New-onset psychosis and emergence of suicidal ideation with aripiprazole.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Quinolones; Suicidal Ideation | 2010 |
Three cases of hypomania and one case of mania during aripiprazole treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Young Adult | 2011 |
Aripiprazole adjunctive to antidepressant therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones | 2011 |
Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotropic Drugs; Quinolones; Retrospective Studies; Stress Disorders, Post-Traumatic; Veterans | 2011 |
Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Databases, Factual; Depressive Disorder, Major; Dibenzothiazepines; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Female; Health Expenditures; Humans; Insurance Claim Review; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Young Adult | 2011 |
Adjunctive antipsychotics for major depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; United States; United States Food and Drug Administration | 2011 |
Comparison of academic and nonacademic sites in multi-center clinical trials.
Topics: Academic Medical Centers; Academies and Institutes; Adult; Antipsychotic Agents; Aripiprazole; Boston; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Hospitals, General; Humans; Interview, Psychological; Male; Middle Aged; Multicenter Studies as Topic; Patient Dropouts; Patient Selection; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Young Adult | 2012 |
The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cross-Cultural Comparison; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Thailand; Young Adult | 2012 |
Adjunctive aripiprazole for depression: predictive value of early assessment.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Health Status Indicators; Humans; Logistic Models; Models, Psychological; Multivariate Analysis; Piperazines; Predictive Value of Tests; Prospective Studies; Psychometrics; Quinolones; Time Factors | 2011 |
Nowhere patients.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Models, Statistical; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2012 |
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Costs; Drug Resistance; Fluoxetine; Health Care Costs; Humans; Piperazines; Quetiapine Fumarate; Quinolones | 2012 |
Aripiprazole monotherapy-related gray-matter growth in a patient with first-episode drug-naïve non-psychotic major depressive disorder.
Topics: Aripiprazole; Brain; Depressive Disorder, Major; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Piperazines; Quinolones | 2012 |
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon?
Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Piperazines; Quinolones; Recurrence | 2012 |
Aripiprazole for the treatment of involuntary movement symptoms in patients with major depressive disorder.
Topics: Aripiprazole; Depressive Disorder, Major; Dyskinesias; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2012 |
Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010).
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cohort Studies; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Prescriptions; Drug Therapy, Combination; Drugs, Investigational; Female; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Retrospective Studies; Spatio-Temporal Analysis; United States; United States Food and Drug Administration; Young Adult | 2013 |
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Depressive Disorder, Major; Humans; Linear Models; Piperazines; Placebo Effect; Quinolones; Randomized Controlled Trials as Topic; Research Design | 2013 |
Aripiprazole as an adjunctive treatment for refractory major depression.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones | 2004 |
Aripiprazole-induced seizure.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Diagnosis, Differential; Epilepsy, Complex Partial; Humans; Male; Piperazines; Quinolones | 2005 |
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2005 |
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Research Design; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2005 |
Aripiprazole-induced parkinsonism.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Male; Middle Aged; Parkinsonian Disorders; Piperazines; Quinolones | 2006 |
Aripiprazole-related tardive dyskinesia.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Quinolones | 2006 |
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones | 2007 |
Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Middle Aged; Monoamine Oxidase Inhibitors; Piperazines; Quinolones; Tranylcypromine; Treatment Outcome | 2007 |
Reversal of trichotillomania with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Morpholines; Piperazines; Quinolones; Reboxetine; Self Concept; Sertraline; Social Adjustment; Trichotillomania | 2008 |
A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Ephedrine; Feeding and Eating Disorders; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 2007 |
Effectiveness of aripiprazole in treating obsessive compulsive symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |